Document is current
Any future updates will be listed below
-
Authors
Raunio, Anna
Kivistö, Ville
Kero, Mia
Tuimala, Jarno
Savola, Sara
Oinas, Minna
Kok, Eloise
Colangelo, Kia
Paetau, Anders
Polvikoski, Tuomo
Tienari, Pentti J.
Puttonen, Henri
Myllykangas, Liisa https://orcid.org/0000-0002-2237-5466
-
Funding
Funding for this research was provided by:
Terveyden Tutkimuksen Toimikunta (341007)
Helsingin ja Uudenmaan Sairaanhoitopiiri (TYH2020231, TYH2022316)
Medicinska Understödsföreningen Liv och Hälsa
- License Information
-
More Information
Article History
Received: 28 November 2022
Accepted: 29 November 2022
First Online: 12 December 2022
Declarations
:
: The Ethics Committee of the Health Centre of the City of Vantaa and the Ethics Committee of the Helsinki and Uusimaa Hospital District approved the study. Health and social work records and death certificates were permitted by the Finnish Health and Social Ministry and the National Authority for Medicolegal Affairs (VALVIRA) approved the collection of the tissue samples and their use for research. Informed consent was obtained from all individual participants or their relatives.
: Pentti J. Tienari holds a patent on C9orf72 in the diagnostics and treatment of ALS/FTD and has made paid consultations for Roche, Biogen, Merck, Teva, Sanofi-Genzyme and Novartis. All other authors declare no conflicts of interest.
